Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.

ABSTRACT:

Background

For the past five years, our annual reports have been tracking the clinical development of new drug-based therapies for the neurodegenerative condition of Parkinson's disease (PD). These reviews have followed the progress both of "symptomatic treatments" (ST - improves/reduces symptoms of the condition) and "disease-modifying treatments" (DMT - attempts to delay/slow progression by addressing the underlying biology of PD). Efforts have also been made to further categorize these experimental treatments based on their mechanisms of action and class of drug.

Methods

A dataset of clinical trials for drug therapies in PD using trial data downloaded from the ClinicalTrials.gov online registry was generated. A breakdown analysis of all the studies that were active as of

SUBMITTER: McFarthing K 

PROVIDER: S-EPMC11307066 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature